文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗丙型肝炎后肝细胞癌短期发病率未增加:一项ERCHIVES研究

The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
PubMed 文献 · Hepatology · 2018-04-19

基于ERCHIVES数据库的回顾性人群队列研究纳入17836人,比较直接抗病毒药物(DAA)与干扰素(IFN)方案治疗后肝细胞癌(HCC)短期发病率。全体治疗者中DAA组HCC风险未高于IFN组(HR 1.07,95%CI 0.55-2.08);获持续病毒学应答的肝硬化者中两组HCC发病率与无HCC生存无显著差异。未治疗肝硬化者HCC发病率显著高于任一治疗组。

要点

  • 全体治疗者中DAA组HCC风险未高于IFN组(HR 1.07,95%CI 0.55-2.08)。
  • 获持续病毒学应答的肝硬化者中,DAA组与IFN组HCC发病率分别为21.2与22.8/1000人年(P=0.78),无HCC生存log-rank P=0.17。
  • 未治疗肝硬化者HCC发病率为45.3/1000人年,显著高于IFN或DAA治疗者(P=0.03)。

核心结论

  • 短期来看,DAA治疗与慢性HCV感染肝硬化者的HCC风险升高无关。
  • 既往报告的DAA治疗相关HCC高发病率可能由IFN治疗者基线HCC危险因素相对较少及选择偏倚解释,因DAA方案用于治疗HCC发生风险更高者。

研究设计与样本

  • 回顾性、人群为基础的队列研究,使用ERCHIVES(Electronically Retrieved Cohort of HCV Infected Veterans)数据库。
  • 队列共17836人,比较DAA方案与IFN为基础方案治疗后HCC发生情况。

主要发现

  • IFN组与DAA组的持续病毒学应答率分别为66.6%与96.2%。
  • 全体治疗者中,DAA组较IFN组的HCC风险未升高(风险比1.07;95%CI 0.55,2.08)。
  • 获持续病毒学应答的肝硬化者中,DAA组与IFN组HCC发病率分别为21.2与22.8/1000人年(P=0.78),无HCC生存log-rank P=0.17。
  • 未治疗肝硬化者HCC发病率为45.3/1000人年,显著高于IFN或DAA治疗者(P=0.03)。
  • 两组治疗者发生HCC的概率均显著低于未治疗者(log-rank P=0.0004)。

局限性

  • 原文结论指出,既往报告的DAA治疗相关HCC高发病率可能由IFN治疗者基线HCC危险因素相对较少及选择偏倚解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Recent studies have reported higher rates of hepatocellular carcinoma (HCC) in individuals treated with direct-acting antivirals (DAAs). However, making definitive conclusions has been challenging because of the heterogeneous populations and methodologies of these reports. We investigated whether DAA use is associated with higher rates of incident HCC compared to treatment with interferon (IFN)-based regimens. We performed a retrospective, population-based cohort study using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database. In a cohort of 17,836 persons, sustained virological response (SVR) was achieved by 66.6% and 96.2% of the IFN and DAA groups, respectively. Among all treated persons, risk of HCC was not higher in the DAA group compared to the IFN group (hazard ratio, 1.07; 95% confidence interval, 0.55, 2.08). Among persons with cirrhosis who achieved SVR, neither the HCC incidence rate nor HCC-free survival were significantly different in the DAA group compared to the IFN group (21.2 vs. 22.8 per 1,000 person-years; P = 0.78 and log-rank P = 0.17, respectively). Untreated persons with cirrhosis had a significantly higher HCC incidence rate (45.3 per 1,000 person-years) compared to those treated with either IFN or DAAs (P = 0.03). Both groups of treated persons had significantly lower probability of HCC development compared to untreated persons (log-rank, P = 0.0004). CONCLUSION: DAA treatment is not associated with a higher risk of HCC in persons with cirrhosis with chronic HCV infection in the short term. Previously reported higher rates of HCC associated with DAA treatment may be explained by both the presence of relatively fewer baseline HCC risk factors in persons treated with IFN as well as selection bias, given that DAA regimens were used to treat persons at higher risk for developing HCC. (Hepatology 2018;67:2244-2253).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 2018. PMID: 29205416. doi:10.1002/hep.29707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。